The estimation of direct medical costs of treating patients with chronic hepatitis B and C in Iran

International Journal of Preventive Medicine

Volumn 3, Issue 3, 2012, Pages 191-196

  Kalantari, Hamid ^a   Davari, Majid ^b   Akbari, Mojtaba ^c   Hejazi, Seyed Mehdi ^d   Kalantari, Maryam ^e   Zakerin, Shahram ^f   Shahshahan, Zahra ^f  

^a Department of Gastroenterology   (Iran)

^b Health Management and Economics Research Center   (Iran)

^c School of Medicine   (Iran)

^d School of Health Management and Information Sciences ^*  (Iran)

^e ISLAMIC AZAD UNIVERSITY   (Iran)

^f ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Direct medical costs; Hepatitis B; Hepatitis C

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA2B INTERFERON; INTERFERON; LAMIVUDINE; PEGAFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; SILYMARIN; TENOFOVIR; UNCLASSIFIED DRUG;

ARTICLE; CROSS-SECTIONAL STUDY; DESCRIPTIVE RESEARCH; DRUG COST; ECHOGRAPHY; ECONOMIC EVALUATION; HEALTH CARE COST; HEPATITIS B; HEPATITIS C; HUMAN; IRAN; LIVER BIOPSY; MEDICAL FEE;

EID: 84858610645     PISSN: 20087802     EISSN: 20088213     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Davari M, Walley T, Haycox A. Pharmaceutical policy and market in Iran: past experiences and future challenges. J Pharm Health Serv Res 2011;2:47-52.
2. Palfrey Colin, Paul Thomas, Phillips Ceri. Effective Healthcare Management: An Evaluative Approach. Oxford: Blackwell; 2004.
3. Kanwal F, Farid M, Martin P, Chen G, Gralnek IM, Dulai GS, et al. Treatment alternatives for hepatitis B cirrhosis: A cost-effectiveness analysis. Am J Gastroenterol 2006;101:2076-89.
4. Kalantari H, Jalali M. Ten year study of histological variations of liver and laboratory findings in 100 healthy hepatitis B Carriers. Journal of Isfahan Medical School 2003;67:32-4.
5. Kalantari H, Kazemi F, Minakari M. Efficacy of triple therapy with interferon alpha-2b ribavirin and amantadine in the treatment of naïve patients with chronic hepatitis C. Journal of Research in Medical Sciences 2007;12:178-85.
6. Kalantari H, Shahshahan Z, Hejazi SM, Ghafghazi T, Sebghatolahi V. Effects of silybum marianum on patients with chronic hepatitis C. Journal of Research in Medical Sciences 2011;16:287-90
7. Arnot R. The evolving efforts to control hepatitis B virus. Pediatr Infect Dis J 1998;17 (7 Suppl): S26-9.
8. Bréchot C, Jaffredo F, Lagorce D, Gerken G, Meyerzum Büschenfelde K, Papakonstontinou A, et al. Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: Results of a European concerted action. J Hepatol 1998;29:173-83.
9. Kanwal F, Farid M, Martin P, Chen G, Gralnek IM, Dulai GS, et al. Treatment alternatives for hepatitis B cirrhosis: A cost-effectiveness analysis. Am J Gastroenterol 2006;101:2076-89.
10. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM. Treatment alternatives for chronic hepatitis B virus infection: A cost-effectiveness analysis. Ann Intern Med 2005;142:821-31.
11. Drummond M, Sculpher M, Torrance G, O'Brien B, Stoddart G. Methods for Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press; 2005.
12. Longo D, Fauci A, Kasper DL, Hauser S, Jameson J, Loscalzo J. editors. Harrison's principles of internal medicine. 18th ed. New York: McGraw Hill; 2011.
13. Alavian SM, Hajarizade B, et al. Hepatitis B virus infection in Iran: A systematic review. J Hepat Mon 2008;8:281-94.
14. Alavian SM, Ahmadzad-Asl M, et al. Hepatitis C infection in general population of Iran: A systematic review. J Hepat Mon 2009;9:211-23.
15. Hajarizadeh B, Rashidian A, Haghdoost AA, Alavian SM. Estimating the costs of the mass vaccination campaign against hepatitis B in Iranian adolescents. GOVARESH 2009;14:27-34.
16. Lahaye D, Strauss P, Baleux C, Van Ganse W. Cost-benefit analysis of hepatitis-B vaccination. Lancet 1987;2:441-3.
17. Williams JR, Nokes DJ, Medley GF, Anderson RM, The transmission dynamics of hepatitis B in the UK; A mathematical model for evaluating costs and effectiveness of immunization programmes. Epidemiol Infect 1996;116:71-89.
18. Van Damme P, Kane M, Meheus A, Integration of hepatitis B vaccination into national immunization programmes. Br Med J 1997;314:1033-6.
19. Szucs TD, Smala A. Berger K, Windorfer A. Economic evaluation of various hepatitis B immunisation strategies in children and adolescents. Med Klin 1998;93:468-77.
20. Jefferson T, Demicheli V. Is vaccination against hepatitis B efficient? A review of world literature. Health Econ 1994;3:25-37.